copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home - Zenas BioPharma Leading With Intention Our commitment to being a leader in the development and commercialization of therapies for autoimmune diseases is clear With our exceptional team, we believe we can Explore the Zenas Experience
Who We Are - Zenas BioPharma Zenas BioPharma is committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases so that patients with autoimmune diseases can reimagine life
Pipeline - Zenas BioPharma Zenas is committed to being a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases We are advancing a balanced portfolio of complementary mechanisms and modalities with best-in-class blockbuster potential across multiple therapeutic areas
News - Zenas BioPharma Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
Job Openings - Zenas BioPharma Learn more about our open positions and how you can become part of the Zenas experience Together, we can reimage life for patients with autoimmune diseases worldwide
Contact Us - Zenas BioPharma The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc or its affiliated companies All rights reserved
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to . . . HONG KONG and BOSTON, March 23, 2021 (GLOBE NEWSWIRE) — Zenas BioPharma (“Zenas”) launched today as a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world
Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of . . . With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment